The transition occurred in nearly 75% of this study population, and researchers found that a prescription for a non-fluticasone-salmeterol dry-powder inhaler in this group was reported in 14.2% of ...

Doses of fluticasone propionate inhalation powder 50 and 100 mcg twice daily significantly improved FEV1 (15% and 18% change from baseline at Endpoint, respectively) compared with placebo (7% change).

Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...